logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8241845 B1

PDFFull Text
Date of Patent:
Aug. 14, 2012

Filed:

Mar. 16, 2009

Steroid 5α-reductase

Applicants:

James L. Mohler, Buffalo, NY (US);

Mark Titus, Chapel Hill, NC (US);

Olga Kozyreva, Chapel Hill, NC (US);

O. Harris Ford, Iii, Wake Forest, NC (US);

Elsbieta Kawinski, Orchard Park, NY (US);

Yun LI, Orchard Park, NY (US);

Inventors:

James L. Mohler, Buffalo, NY (US);

Mark Titus, Chapel Hill, NC (US);

Olga Kozyreva, Chapel Hill, NC (US);

O. Harris Ford, III, Wake Forest, NC (US);

Elsbieta Kawinski, Orchard Park, NY (US);

Yun Li, Orchard Park, NY (US);

Assignee:

Health Research Inc., Buffalo, NY (US);

Attorney:

Hodgson Russ LLP

Primary Examiner:

Rebecca E Prouty

Int. Cl.
CPC ...
C12Q 1/68 (2006.01); C12Q 1/26 (2006.01); C12N 15/53 (2006.01); C12N 9/02 (2006.01);
U.S. Cl.
CPC ...
Abstract

The invention provides an isolated, novel steroid 5α-reductase enzyme termed SRD5AIII. The protein has an estimated molecular weight of 37 kDa and is capable of converting testosterone to dihydrotestosterone at a pH of about 7.0. Also provided is a method for identifying inhibitors of SRD5AIII by contacting SRD5AIII with a test compound and measuring the activity of the enzyme. A reduced activity relative to a control indicates that the test compound is an inhibitor of SRD5AIII. A method is also provided for detecting androgen stimulated prostate cancer or recurrent prostate cancer in an individual. The method comprises obtaining a prostate biopsy from an individual and determining the level of expression of SRD5AIII gene or protein relative to a normal control. An increased expression of SRD5AIII relative to the control is indicative of androgen stimulated prostate cancer or recurrent prostate cancer.

Find Patent Forward Citations

Loading…